Quoin Pharmaceuticals Q3 net loss widens 23% to $4.87 million
QNRX•Quoin Pharmaceuticals’ third-quarter 2026 net loss widened 23% year over year to $4.87 million, while cash, cash equivalents and marketable securities totaled approximately $33.2 million at September 30. Interim QRX003 Phase 2/3 results achieved statistical significance for the primary and key secondary endpoints.
1. Quarterly results
Quoin Pharmaceuticals’ third-quarter 2026 net loss widened 23% year over year to $4.87 million. Cash, cash equivalents and marketable securities totaled approximately $33.2 million at September 30, 2026.
2. QRX003 study
Interim results from the QRX003 Phase 2/3 Netherton Syndrome study achieved statistical significance for the primary and key secondary endpoints. Management expects to complete recruitment by year-end 2026 and report topline results in the second quarter of 2027.
